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Individuals with type 1 diabetes (T1D) demonstrate varied trajectories of estimated glomerular3
filtration rate (eGFR) decline. The molecular pathways underlying rapid eGFR decline in T1D are4
poorly understood, and individual-level risk of rapid eGFR decline is difficult to predict.5
Methods6
We designed a case-control study with multiple exposure measurements nested within four well-7
characterized T1D cohorts (FinnDiane, Steno, EDC, CACTI) to identify biomarkers associated8
with rapid eGFR decline. Here, we report the rationale for and design of these studies as well as9
results of models testing associations of clinical characteristics with rapid eGFR decline in the10
study population, upon which “omics” studies will be built. Cases (n = 535) and controls (n = 895)11
were defined as having an annual eGFR decline of >3 ml/min/1.73m2 and <1 ml/min/1.73m2,12
respectively. Associations of demographic and clinical variables with rapid eGFR decline were13
tested using logistic regression, and prediction was evaluated using area under the curve (AUC)14
statistics. Targeted metabolomics, lipidomics, and proteomics are being performed using high-15
resolution mass-spectrometry techniques.16
Results17
At baseline, mean age was 43 years, diabetes duration was 27 years, eGFR was 94 ml/min/1.73m2,18
and 62% of participants were normoalbuminuric. Over 7.6 years median follow-up, the mean19
annual change in eGFR in cases and controls was -5.7 ml/min/1.73m2 and 0.6 ml/min/1.73m2,20
respectively. Younger age, longer diabetes duration, and higher baseline HbA1c, urine albumin-21
creatinine ratio, and eGFR were significantly associated with rapid eGFR decline. The cross-22
4
validated AUC for the predictive model incorporating these variables plus sex and mean arterial1
blood pressure was 0.74 (95% CI 0.68, 0.79; p < 0.001).2
Conclusion3
Known risk factors provide moderate discrimination of rapid eGFR decline. Identification of blood4
and urine biomarkers associated with rapid eGFR decline in T1D using targeted omics strategies5




Approximately 25-40% of individuals with type 1 diabetes (T1D) develop diabetic kidney10
disease (DKD), defined as a reduction in estimated glomerular filtration rate (eGFR) or onset of11
albuminuria [1,2]. In this population, the reported incidence of kidney failure ranges from 2-35%12
over 30 years of T1D duration, and up to 60% over 50 years of T1D duration [3,4].13
Progressive eGFR decline is largely a monotonic process that occurs early in the course of14
T1 DKD [5]. The annual rate of decline varies across affected individuals, with more rapid rates15
conferring higher risk of kidney failure [6]. Additionally, eGFR decline may precede the onset of16
albuminuria, suggesting the presence of disease activity before clinical signs are apparent [5,7].17
While various pathophysiological processes including hyperglycemia, microvascular dysfunction,18
inflammation, and fibrosis, are implicated in DKD, the mechanisms underlying the observed19
differential decline in kidney function across individuals remain poorly understood [8,9]. Insight20
into the mechanisms of eGFR decline in T1D is important for early identification of individuals at21
risk for DKD progression and for development of new therapies.22
5
The search is ongoing for novel biomarkers that can parse through the heterogeneous nature1
of DKD pathophysiology and improve the predictive and prognostic abilities of existing clinical2
models for DKD progression [10]. A number of candidate biomarkers have been associated with3
putative pathogenic pathways (including inflammation, endothelial dysfunction, and fibrosis) and4
functional kidney outcomes (such as eGFR decline, albuminuria, and kidney failure) in DKD [11].5
However, their widespread use is limited by lack of validation and diagnostic precision [12-14].6
The development of “omic” approaches has facilitated biomarker identification in DKD7
via quantification of low-molecular weight proteins, metabolites, and lipids in blood and urine8
using refined mass spectrometry techniques [15,16]. A new multidimensional urinary proteome9
classifier (CKD273) has identified new peptide markers of interest and demonstrated promise in10
detecting individuals with diabetes who are at risk for progression of DKD, though studies have11
primarily focused on individuals with type 2 diabetes (T2D) [17,18]. Recently, 125 plasma amino12
acid, triglyceride, and lipid metabolites were cross-sectionally associated with eGFR in a large13
T2D meta-analyses [19]. Among individuals with T1D, use of omic technologies may allow for14
better characterization of the molecular pathways responsible for eGFR decline and enable15
application of this insight to the development of predictive models.16
Recently, an international consortium funded by JDRF was established to identify17
metabolite, lipid, and protein markers of eGFR decline in individuals with T1D using novel multi-18
omics techniques. The aims of the JDRF consortium are (1) to discover and validate a set of19
biomarkers associated with rapid eGFR decline in T1D using novel omics platforms which may20
provide insight into disease mechanisms, and (2) to use resulting omics data to develop predictive21
models for rapid eGFR decline in T1D. In this paper, we describe the rationale, design, cohorts,22
and methods of the JDRF Biomarkers Consortium, and examine associations of clinical variables23
6
with rapid eGFR loss as well as prediction of eGFR loss by clinical variables to establish common,1




We designed a case-control study with multiple exposure measurements to test associations6
of blood and urine biomarkers, measured at baseline, with subsequent rapid eGFR decline in T1D.7
The case-control study was nested within four T1D cohorts. Cases were defined as having an8
annual decline in eGFR of > 3 ml/min/1.73m2 and controls were defined as having an annual9
decline in eGFR of < 1ml/min/1.73m2. Blood and urine samples obtained at baseline are being10
applied to metabolomics, lipidomics, and/or proteomics platforms for measurement of pre-11
specified biomarkers. A discovery-validation approach will be taken to test associations of12
biomarkers with eGFR decline.13
14
Study population15
Our study sample is composed of 1,430 participants (535 cases and 895 controls) from four16
well-characterized T1D cohorts: the Finnish Diabetic Nephropathy study (FinnDiane), the Steno17
Diabetes Center Copenhagen study (Steno), the Epidemiology of Diabetes Complications study18
(EDC) and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI) (shown in Fig.19
1) [20-23]. Subjects were included based on the following criteria: eGFR ≥ 30 ml/min/1.73m2 at20
baseline, follow up of at least 2 years, ≥ 3 longitudinal eGFR measurements, and baseline urine21
and blood sample availability. In FinnDiane, cases and controls were frequency-matched by22
albuminuria strata (normoalbuminuria, microalbuminuria, macroalbuminuria). In the three23
7
remaining cohorts, all participants who met the definition of case or control and met the stated1
criteria were included. To maintain consistency across cohorts given their extended durations, only2
participants examined between 1995 and 2011 were included.3
Details on protocols and data collection for each cohort have been previously published4
and are summarized in the Supplementary Text. Briefly, the FinnDiane cohort includes adults with5
T1D from healthcare centers across Finland who were evaluated regularly [20]. The Steno cohort6
includes adults with T1D who attended the Steno Diabetes Center Copenhagen and were followed7
for a median of 4.7 years [21]. The EDC cohort includes subjects with childhood-onset T1D8
diagnosed or seen within one year of diagnosis at Children’s Hospital of Pittsburgh between 1950-9
1980 who were examined in 1986-88, then biennially for 10 years with additional examinations at10
18 and 25 years [22]. The CACTI cohort includes adults with T1D without a history of11




Glomerular filtration rate was estimated using the CKD-EPI creatinine equation in all16
cohorts [24]. Laboratory methods for serum creatinine measurements differed by study cohort and17
are detailed in the Supplementary Text. Annual rate of eGFR decline was calculated by fitting18
regression lines to serial eGFR values (FinnDiane, Steno) or by dividing absolute eGFR change19
from baseline to last study visit by the number of years between these (EDC, CACTI).20
21
Measurement of biological samples22
8
Baseline timed urine and fasting plasma samples were obtained from each cohort.1
Coordinated shipping and storage efforts were undertaken to preserve biosample integrity and2
reduce the number of freeze-thaws. Frozen biosamples were stored in a central laboratory at3
University of California San Diego (UCSD), where they were entered into a sample-tracking4
database. Sample aliquots were transferred to platform sites for omics analysis and remain stored5
at -80°C.6
Targeted metabolomic, lipidomic, and proteomic measurements and analyses are currently7
being performed concurrently at UT Health Science Center San Antonio/UCSD, University of8
Michigan, and University of Washington, respectively. Biomarkers measured in each platform are9
pre-specified based on existing scientific evidence of an association with DKD (Supplementary10
Table 1). Biomarkers are being quantified using targeted mass-spectrometry with inclusion of11
stable isotope-labeled standards to enhance accuracy and reduce variation across measurements.12
Strict quality control methods are employed to monitor instrument accuracy and batch-to-batch13
variation. The same techniques are being used to measure biomarkers in discovery and validation14
sets. Biomarkers that differ significantly between cases and controls will be considered for more15
precise quantification using orthogonal high throughput, quantitative assays.16
17
Metabolomics18
Previously, 13 out of 94 urine metabolites were found to differ between DKD and diabetes19
alone in a cross-sectional study of 108 participants [25]. These 13 metabolites, along with select20
organic acids, amino acids, purines, and pyrimidines identified by collaborators as being associated21
with DKD, are being measured in baseline urine and plasma samples using targeted gas22
9
chromatography-mass spectrometry (GC-MS) and tandem liquid chromatography-mass1
spectrometry (LC-MS) techniques [26,27].2
3
Lipidomics4
Earlier works identified plasma lipid alterations associated with CKD and T2 DKD5
progression [28-30]. A targeted LC-MS/MS assay was developed to quantify free fatty acids,6
acylcarnitines, and other members of complex lipid classes hypothesized to have an association7




Urine proteins were selected for measurement following a comprehensive literature review12
which identified 179 candidate proteins from 12 signaling pathways involved in DKD across13
animal and human studies. Thirty-eight tryptic peptides derived from 20 of these proteins could be14
reliably measured using protein precipitation and proteolysis-LC-MS/MS with adequate15




Clinical variable association and prediction studies20
We developed and evaluated models of eGFR decline using clinical covariates to21
understand these associations and provide a foundation for biomarker analyses.22
10
We first summarized the distribution and central tendencies of clinical variables, then fit1
clinical covariate data in logistic regression models to test associations of clinical variables with2
case versus control status. We developed three nested models: Model 1 included demographics3
(age at entry and sex); Model 2 included demographics, diabetes duration, and baseline HbA1c4
levels, urine albumin-creatinine ratio (UACR), and mean arterial pressure (MAP, defined as5
[(systolic blood pressure + (2 × diastolic blood pressure))/3]); Model 3 added baseline eGFR level6
to Model 2. Odds ratios with 95% CIs were calculated for each variable.7
Area under the Receiver Operating Characteristic curve (AUC) values were calculated to8
evaluate model discrimination, and DeLong’s test was used to compare nested model AUCs [31].9
To accurately estimate model performance in future samples, we used repeated random sub-10
sampling validation, training models on a random 4/5th of the sample then testing these on the11
held-out 1/5th. AUCs were calculated on the 1/5th sample. This training-testing process was12
repeated 500 times providing a distribution of test AUC estimates, from which a median and 95%13
CI were estimated.14
Next, we compared model parameters according to four baseline eGFR strata:15
30≤eGFR≤60 ml/min/1.73m2; 60<eGFR≤90 ml/min/1.73m2; 90<eGFR≤120 ml/min/1.73m2; and16
120<eGFR≤150 ml/min/1.73m2. Interaction terms between this categorical eGFR variable and17
covariates were tested via likelihood ratio tests. If model fit improved significantly at 5%18
significance, separate models were fit for each stratum and cross-validated AUCs were calculated19
for stratified models. Finally, to test if the stratum-specific models improved discrimination, we20
used bootstrap resampling to compare AUCs of stratified and full models [32]. AUCs were21
calculated on each of 500 bootstrap samples. The difference between the full sample and stratum-22
specific AUCs were recorded. The 500 bootstrapped differences were used to calculate percentile23
11
intervals and test if stratum-specific AUCs differed from the full sample AUC. If the interval1
excluded zero, we inferred that the AUCs were statistically different. This analysis was repeated2
for baseline albuminuria strata defined by normoalbuminuria (UACR <30mg/g),3
microalbuminuria (30≤UACR<300 mg/g), and macroalbuminuria (UACR ≥300mg/g). When4




Our sample comprised 1430 subjects from the four T1D cohorts, including 535 cases and9
895 controls (Table 1). Subjects’ mean age was 43 years, 50% were female, and mean (SD)10
diabetes duration was 26.8 (12.6) years. The mean (SD) HbA1c and eGFR were 8.5 (1.3)% and11
94 (24) ml/min/1.73m2, respectively, and median UACR (25th, 75th %ile) was 12 (5, 64) mg/g.12
Subjects were followed for a median (25th, 75th %ile) of 7.6 (4.9, 11.7) years.13
Compared with control participants, cases were on average younger, had higher average14
baseline levels of HbA1c, blood pressure, eGFR, and UACR compared to controls (Table 1). The15
mean (SD) annual eGFR slope  was -5.65 (4.53) ml/min/1.73m2 in cases, versus 0.57 (1.87)16
ml/min/1.73m2 in controls.17
18
Characteristics associated with eGFR decline19
Younger age at study entry was associated with greater risk of rapid eGFR decline in the20
demographics-only model (Model 1), which had an AUC of 0.61 (Table 2). In Model 2, younger21
age, higher HbA1c, and higher UACR were associated with rapid eGFR decline. Compared to the22
demographics-only model, Model 2 had a significantly higher AUC of 0.69 (p = 0.0015). In the23
12
fully-adjusted model (Model 3) comprising demographic and clinical variables, younger age,1
longer diabetes duration, and higher HbA1c, UACR, and eGFR conferred greater risk of rapid2
eGFR decline. Specifically, every 10 more years of age was associated with a 24% lower odds of3
rapid eGFR decline, every 10 more years of diabetes duration was associated with a 20% higher4
odds of rapid eGFR decline, each 1% higher HbA1c was associated with a 15% higher odds of5
rapid eGFR decline, each two-fold greater UACR was associated with a 30% higher odds of rapid6
eGFR decline, and every 10 ml/min/1.73m2 greater baseline eGFR was associated with a 31%7
higher odds of rapid eGFR decline. Compared to the demographics-only model, Model 3 had a8
significantly higher AUC of 0.74 (p < 0.001).9
10
Consideration of additional risk factors11
When added to Model 3, the presence of hypertension (as a binary indicator) was12
significantly associated with rapid eGFR decline (OR 1.46; 95% CI 1.09, 1.96). Neither13
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use,14
presence of retinopathy, nor smoking history (past, current, never smoker) were significantly15
associated with rapid eGFR decline. When added to Model 3, neither the presence of hypertension,16
ACEi or ARB use, the presence of retinopathy, nor smoking history improved model17
discrimination. Thus, we conducted all subsequent subgroup analyses based on Model 3 to18
minimize the impact of missing information (Supplementary Table 2).19
20
Subgroup analysis21
Addition of interactions between baseline eGFR or UACR strata and clinical variables22
improved the fit of the logistic model significantly (likelihood ratio p-value < 0.001). Hence, we23
13
applied Model 3 to eGFR, UACR, and combined eGFR and UACR strata with sufficient sample-1
sizes (Supplementary Table 2). The directions of association for the predictors with rapid eGFR2
decline in the stratified models were similar to those in the full cohort models. Notably, the3
magnitude of the association of UACR with rapid eGFR decline was greater in the eGFR 60-4
90ml/min/1.73m2 group (OR 1.39; 95% CI 1.27, 1.53) compared to groups with higher eGFRs5
(OR 1.10-1.24). Additionally, while higher HbA1c was significantly associated with rapid eGFR6
decline in groups with microalbuminuria (OR 1.36; 95% CI 1.14, 1.65) and macroalbuminuria7
(OR 1.66; 1.24, 2.29), this association was not observed in the normoalbuminuria group.8
Figure 2 depicts the median (95% CIs) cross-validated AUCs. There was substantial9
variability in discrimination across baseline kidney function categories compared to the full cohort10
AUC, with cross-validated AUCs ranging from 0.59 to 0.76. The lowest AUCs were observed in11
the eGFR 120-150 ml/min/1.73m2 group (AUC 0.59), the macroalbuminuria group (AUC 0.65),12
and the combined normoalbuminuria and eGFR 90-120 ml/min/1.73m2 group (AUC 0.65).13
14
DISCUSSION/CONCLUSION15
We have assembled a collection of well-defined T1D cohorts to identify biomarkers16
associated with rapid eGFR decline. While demographic and clinical variables were significantly17
associated with rapid eGFR decline in these cohorts, these do not predict rapid eGFR decline with18
sufficient precision. Our expectation is that omics-derived urine and plasma biomarkers will be19
associated with rapid eGFR decline, independent of demography and clinical variables, and20
enhance the predictive ability of our models.21
Our use of four large, multi-national, rigorously-derived T1D cohorts leaves us well-22
positioned to identify biomarkers associated with rapid eGFR decline. These T1D cohorts have23
14
large sample sizes, prolonged follow-up, and excellent participant retention. Additionally, each1
cohort has used standardized methods for participant recruitment, data collection, and biosample2
preservation. Furthermore, availability of timed urine and fasting plasma samples in all cohorts3
increases the precision of biomarker measurements and facilitates comparisons across cohorts. The4
clinical models developed here will be used as the base for discovery and validation omics5
analyses. Biomarkers associated with rapid eGFR decline will be incorporated into predictive6
models made using clinical variables and AUC values for these will be calculated to assess model7
discrimination.8
We found that younger age, longer diabetes duration, and higher baseline HbA1c, UACR,9
and eGFR were associated with rapid eGFR decline in our study population. Overall, these10
findings are consistent those observed in other T1D and T2D populations [33-36]. Notably, a two-11
fold higher UACR was associated with 30% greater odds of rapid eGFR decline in our fully-12
adjusted model. However, this association is difficult to interpret and may be biased towards the13
null because of matching of case-control status by albuminuria strata in one of our study cohorts.14
To build a foundation for assessing the predictive ability of measured biomarkers, we derived15
prognostic models using these clinical variables. We found that overall model discrimination was16
moderate (AUC = 0.74) using age, sex, diabetes duration, HbA1c, blood pressure, albuminuria,17
and baseline eGFR as predictors of rapid eGFR decline. Similarly-derived models focusing on18
incident DKD or major kidney-related events as outcomes have had greater predictive success [14,19
37].20
The relatively low discriminatory potential of our model could be explained by our focus21
on an outcome which occurs early in the course of DKD as well as by the high average baseline22
eGFR in our cohort [33]. Interaction testing confirmed that associations between covariates and23
15
rapid eGFR decline differed according to baseline kidney function. Subgroup analyses revealed1
that model discrimination varied by strata of baseline eGFR and albuminuria. Specifically, the2
model demonstrated poor predictive ability among those with baseline eGFR 120-3
150ml/min/1.73m2 (AUC = 0.59), baseline macroalbuminuria (AUC = 0.65), and baseline eGFR4
90-120ml/min/1.73m2 and normoalbuminuria (AUC = 0.65). The difficulty in predicting eGFR5
decline in these subgroups may reflect variable biologic underpinnings of eGFR decline, though6
regression to the mean may also contribute to these findings. Overall, weak-to-moderate AUCs,7
especially when eGFR and albuminuria are in the normal range, highlight the need for prognostic8
biomarkers capable of early identification of high-risk individuals.9
Using novel, targeted omics strategies, we plan to identify plasma and urine biomarkers10
associated with rapid eGFR decline which elucidate mechanisms of T1 DKD and build on clinical11
predictive models. Numerous biomarkers belonging to pathways implicated in DKD, including12
inflammation, endothelial dysfunction, and fibrosis, have been associated with DKD-related13
outcomes in cross-sectional and longitudinal studies [11]. At the same time, questions remain14
regarding the specific molecules comprising these pathogenic pathways and how they contribute15
to eGFR decline in DKD. This is partly because of heterogeneity across existing studies in clinical16
outcomes, chosen biomarkers, and methods of biomarker quantification, which has made17
biomarker validation challenging [11].18
There has been increasing interest in the association of biomarkers with eGFR decline in19
DKD [38, 39]. Our panel of 13 urine metabolites was recently found to correlate with eGFR slope20
in 1,001 subjects with T2D in the Chronic Renal Insufficiency Cohort study [40]. Notably, this21
panel was responsive to therapy with dapagliflozin and atrasentan, suggesting potential as a22
surrogate indicator for mitochondrial dysfunction in T2D [41,42]. Members of our group have also23
16
identified 125 plasma metabolites associated with eGFR in a meta-analysis including 3,0891
samples from participants of five independent Dutch T2D cohort studies [19]. Similar biomarker2
advances have also been made in T1D, albeit in relatively smaller study populations. Serum3
lipidomic measurements of 669 individuals with T1D from Steno identified cross-sectional4
associations between phosphatidylcholine and sphingomyelin species and eGFR and albuminuria,5
out of which 13 lipids were longitudinally associated with eGFR or albuminuria slope [15]. Serum6
metabolomic measurements in this cohort additionally revealed ribonic acid and myo-inositol to7
be inversely associated with >30% eGFR decline [16] Also, in a study of 465 individuals with8
T1D from CACTI, a panel of 4 out of 252 urine peptides identified in a label-free discovery9
analysis improved prediction of annual eGFR decline > 3.3% and/or development of albuminuria10
when added to DKD risk factors (increase in AUC from 0.84 to 0.89) [43].11
These promising results underscore the need to further study eGFR decline in T1D using12
large cohorts and refined, combined multi-omic assays. In our study we propose to use these13
strategies to develop a robust set of biomarkers which are specific to this population, internally14
and externally validated, and have multi-national applicability. Additionally, our use of a15
hypothesis-driven, targeted omics approach that will yield highly precise, quantitative, and16
reproducible results is conducive to our goals of deciphering mechanisms of eGFR decline and17
improving prediction of this outcome.18
Our work may serve as a foundation on which future omics research can build. Added19
insight into pathological pathways may encourage generation of new diagnostic tests and therapies.20
Following extensive validation and assay optimization, identified biomarkers may be able to act21
as surrogates for risk of eGFR decline in T1D. This could facilitate recruitment and increase22
efficiency in clinical trials, as those at increased risk for poor outcomes are more likely to benefit23
17
from therapeutic interventions. Ultimately, we hope to integrate metabolomic, lipidomic, and1
proteomic biomarker data with kidney tissue-derived genetic and transcriptional network data2
using systems biology and computational bioinformatic techniques with the goal of3
mechanistically defining pathologic DKD subgroups. By then associating molecularly defined4
subgroups with clinical characteristics and kidney outcomes, we aim to develop a functional5
framework for rapid eGFR decline in T1D.6
Our study has several limitations. Our population is primarily white, limiting applicability7
of results to wider ranges of races and ethnicities. We defined case-control status using a linear8
estimation of eGFR decline, though eGFR trajectories may exhibit non-linear patterns. However,9
existing evidence suggests that non-linear eGFR decline occurs only in a minority [33]. A10
substantial proportion of our study population has a baseline eGFR >90 ml/min/1.73m2, a range in11
which changes in eGFR are difficult to ascertain. The observation that cases had higher baseline12
eGFR than controls is likely due to participant selection, as subjects with higher baseline eGFR13
have more capacity to reach the threshold for case definition. In this group, a “therapeutic” decline14
in eGFR resulting from reduced “hyperfiltration” is difficult to distinguish from a “pathologic”15
one. We have defined rapid versus slow decline based on extremes of the eGFR slope distribution16
and have determined slopes over prolonged follow-up periods, which should reduce17
misclassification. At the same time, since models were developed using extremes of the eGFR18
slope distribution, the discriminatory ability of these models would be attenuated by application19
to a broader cohort with a wide range of eGFR slopes. Also, as mentioned above, the association20
of UACR with rapid eGFR decline should be interpreted with caution due to matching of case-21
control status by albuminuria strata in one of our study cohorts. With respect to our biomarker22
analyses, prolonged storage and inconsistencies in biosample collections across cohorts could23
18
influence the accuracy and sensitivity of measurements. Additionally, though biomarkers present1
in small quantities may be difficult to detect, our targeted approach represents the optimal strategy2
for increasing measurement precision.3
In conclusion, we have assembled a large, multinational T1D cohort for determining4
metabolic, lipid, and protein biomarkers associated with rapid eGFR decline. In this cohort, clinical5
factors alone are insufficient in predicting rapid eGFR decline, especially among those with normal6
baseline kidney function. Our application of novel, targeted omics approaches may help improve7
understanding of the mechanisms underlying rapid eGFR decline and may facilitate identification8
of those at risk for this outcome.9
10
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Fig. 1. Study design of JDRF Biomarkers Consortium, a case-control study nested in four T1D3
cohorts.4
5
Fig. 2. Performance of demographic and clinical variables in the prediction of rapid eGFR loss6
according to baseline eGFR and urine albumin-creatinine ratio. Presented values are cross-7
validated area under the curve (AUC; median 95% CI).8
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Cases 535 (37) 299 (52) 53 (15) 66 (45) 117 (34) - -
Demographics
Female sex 721 (50) 300 (52) 154 (43) 75 (51) 192 (56) 277 (52) 444 (50)
Age (years) 42.8 (12.7) 41.3 (12.4) 52.8 (12.0) 37.3 (7.9) 37.2 (9.1) 39.6 (12.6) 44.7 (12.4)
Race & ethnicity
White 1400 (98) 578 (100) 362 (100) 140 (96) 320 (93) 518 (97) 882 (99)
Black 11 (1) 0 (0) 0 (0) 6 (4) 5 (1) 6 (1) 5 (1)
Hispanic 10 (1) 0 (0) 0 (0) 0 (0) 10 (3) 8 (1) 2 (0)
Smoking history
Never 579 (40) 266 (46) 0 (0) 91 (62) 222 (65) 245 (46) 334 (37)
Past 238 (17) 131 (23) 0 (0) 33 (23) 74 (22) 103 (19) 135 (15)
Current 213 (15) 153 (26) 0 (0) 16 (11) 44 (13) 114 (21) 99 (11)
Medical history and clinical
characteristics
Diabetes duration (years) 26.8 (12.6) 25.6 (12.3) 30.9 (16.0) 29.3 (7.6) 23.5 (9.0) 25.8 (12.2) 27.4 (12.8)
Retinopathy status
Present 658 (46) 263 (46) 228 (63) 71 (49) 96 (28) 235 (44) 423 (47)
Not present 709 (50) 309 (53) 77 (21) 75 (51) 248 (72) 278 (52) 431 (48)
Mean Arterial Pressure
(mmHg)











131.3 (20.6) 129.1 (18.7)
Diastolic Blood Pressure
(mmHg)
77.0 (10.2) 79.3 (10.2) 76.4 (10.4) 69.8 (9.7) 76.8 (8.8) 78.0 (10.6) 76.4 (10.0)
ACEi or ARB use
Yes 440 (31) 290 (50) 230 (64) 33 (23) 117 (34) 246 (46) 424 (47)
No 624 (44) 284 (49) 132 (36) 113 (77) 227 (66) 286 (53) 470 (53)
Hypertension diagnosis
Yes 643 (45) 395 (68) 74 (20) 25 (17) 149 (43) 283 (53) 360 (40)
No 725 (51) 179 (31) 231 (64) 121 (83) 194 (56) 230 (43) 495 (55)
Laboratory data at baseline
HbA1c (%) 8.5 (1.3) 8.7 (1.6) 8.7 (0.7) 8.4 (1.4) 8.1 (1.3) 8.7 (1.6) 8.3 (1.1)


















Macro: > 300 mg/g 143 (10) 80 (14) 24 (7) 13 (9) 26 (8) 99 (19) 44 (5)
Micro: >30, < 300 mg/g 323 (23) 159 (28) 91 (25) 34 (23) 39 (11) 134 (25) 189 (21)
Normal < 30 mg/g 881 (62) 286 (49) 246 (68) 99 (68) 250 (73) 269 (50) 612 (68)
eGFR slope
(ml/min/1.73m2/y)
-1.8 (4.4) -3.0 (4.0) -0.2 (5.0) -2.5 (2.7) -1.1 (4.2) -5.7 (4.5) 0.6 (1.9)
* Case: eGFR slope/yr ≤ -3 ml/min/1.73m2
**Control: eGFR slope/yr > -1 ml/min/1.73m2
Entries are mean (SD) for continuous variables and N (%) for categorical variables, unless otherwise
indicated. Percentages are calculated as percent of total values.
Number (%) of missing values for each variable in the overall study population: race & ethnicity 9 (1),
smoking history 400 (28), diabetes duration 1 (<1), retinopathy status 63 (4), MAP 7 (<1), SBP 7 (<1),
DBP 7 (<1), antihypertensive medication 4 (<1), hypertension diagnosis 62 (4), HbA1c 8 (1), baseline
UACR 83 (6).
JDRF = Juvenile Diabetes Research Foundation; CACTI = Coronary Artery Calcification in Type 1
diabetes study; EDC = Pittsburgh Epidemiology of Diabetes Complications study; FinnDiane = Finnish
Diabetic Nephropathy Study; Steno = Steno Diabetes Center Study; ACEi = angiotensin-converting
enzyme inhibitor; ARB = angiotensin receptor blocker
Table 2: Associations of clinical characteristics with rapid eGFR decline among participants from







Age (per 10 years) 0.72  (0.66, 0.79)* 0.63  (0.56, 0.72)* 0.76  (0.66, 0.87)*
Sex (ref: female) 0.99  (0.80, 1.24) 0.89  (0.70, 1.13) 0.82  (0.64, 1.05)
Diabetes duration (per 10 years) 1.13  (0.99, 1.29) 1.20 (1.05, 1.37)*
HbA1c (per 1%) 1.17  (1.07, 1.29)* 1.15  (1.05, 1.27)*
Mean Arterial Pressure (per 10
mmHg)
1.08  (0.96, 1.21) 1.11  (0.99, 1.25)
UACR (per doubling) 1.19  (1.13, 1.25)* 1.30  (1.23, 1.38)*
eGFR (per 10 ml/min/1.73m2) 1.31  (1.23, 1.41)*
AUC median
(95% CI)
0.61  (0.56, 0.67) 0.69  (0.63, 0.75) 0.74  (0.68, 0.79)
Full Cohort:  N = 1430; N (cases) = 535. Cell contents are odds ratios (OR) and 95% CI from logistic
regression models, as well as cross-validated area under the curve (AUC; median 95% CI).
*p < 0.05
Fig. 1. Study design of JDRF Biomarkers Consortium, a case-control study nested in four T1D
cohorts.
Fig. 2. Performance of demographic and clinical variables in the prediction of rapid eGFR loss
according to baseline eGFR and urine albumin-creatinine ratio.
Presented values are cross-validated area under the curve (AUC; median 95% Cl).
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Supplementary Text: Description of the four study cohorts
The Finnish Diabetic Nephropathy (FinnDiane) study cohort
The FinnDiane study is a prospective nationwide multicenter study of more than 8,400 adults
with T1D from 21 university and central hospitals, 33 district hospitals, and 26 primary health care
centers across Finland and is the largest natural history study for T1D and its complications [1]. Patients
are followed on a yearly basis and kidney function is measured via urine albumin excretion rates and
eGFR measurements. The current study comprises 578 cases and controls studied between 1998 and
2011. Patients participated in the study during a regular visit to their attending physician during which
detailed demographic and medical history data were collected with standardized questionnaires. Blood
pressure was measured two times with 2-min intervals in the sitting position after an initial 10-min rest
and the mean values were used for analysis. Hypertension was defined as > 130/85 mmHg over two
readings or use of antihypertensive medication. HbA1c was measured with standard methods at the local
centers; eGFR was estimated from serum creatinine values by the CKD-EPI equation [2]. Annual rate of
eGFR change was calculated by fitting regression lines to serial eGFR measures for each patient. A
participant was classified as having retinopathy if he/she received laser treatment. In a subset of 1,346
FinnDiane patients, that had been ETDRS graded from fundus photographs and ophthalmic records, we
observed that 81.1% of laser-treated patients eventually were diagnosed with proliferative diabetic
retinopathy [3]. This suggests that laser treatment could be used as a surrogate for severe retinopathy in
FinnDiane. As the training of the Finnish ophthalmologists is uniform (one main instructor in the
country the last 35 years) the indications for laser treatment at different centers are consistent.
All participants gave written consent prior to participation, and the study protocol was approved
by the local ethics committees of each participating center. The study is performed in accordance with
the Declaration of Helsinki as revised in the year 2000.
3
The Steno study cohort
The Steno Diabetes Center Copenhagen (SDCC) is specialized in the treatment, research and
prevention of diabetes and in the education of healthcare professionals [4]. It is Scandinavia’s largest
diabetes clinic (www.sdcc.dk).
The current study cohort is comprised of Caucasian adults (age ≥18 years) with T1D attending
the SDCC out-patient clinic. Their follow up time ranges from 4 to 10 years (median 4.65 years). The
SDCC T1D sample may be sub-grouped on the basis of their baseline examination dates. The first set of
T1D cases was enrolled between May 1995 to April 1996 while participating in the Low Protein Diet
(LPD) study with a T1D onset of at least 10 years [5]. The second set of T1D cases were enrolled in
2004 for a study of biomarkers related to nephropathy, while the last set of T1D cases were enrolled
between 2009-2011 and participated in a study of biomarkers of nephropathy and arterial stiffness [6,7].
Patient demographics, biochemical measurements, and medical history data were collected at
each follow-up visit. Blood pressure measures were recorded with either a validated tonometric device
(BPro; HealthStats, Singapore), or using the Hawksley Random Zero Sphygmomanometer, with a mean
of at least two measures [5,7]. Hypertension was defined as use of antihypertensive medication. High-
performance liquid chromatography (Bio Rad Laboratories, Munich, Germany) was used to estimate
HbA1c (normal range: 4.1-6.4%) and an enzymatic method (Hitachi 912; Roche Diagnostics,
Mannheim, Germany) was used to measure serum creatinine concentrations [7]. Urinary albumin
excretion ratio (UAER) was measured in 24-h sterile urine collections by enzyme immunoassay; eGFR
was calculated using the CKD-EPI creatinine equation. The rate of decline in kidney function was
analyzed with regression lines for eGFR over the follow-up period using all measurements of eGFR
during the study period. Retinopathy was assessed via retinal photographs taken during regular
ophthalmologic examinations. All participants gave written informed consent, and the study was
approved by the Danish National Ethics committee. A total of 362 Steno cases and controls are included
in the current analysis.
4
Epidemiology of Diabetes Complications (EDC) study cohort
The EDC is a prospective historical cohort study based on incident cases of childhood onset (<17
years) T1D, diagnosed or seen within one year of diagnosis (1950-80) at Children’s Hospital of
Pittsburgh [8]. The cohort, which has been shown to be epidemiologically representative of the
Allegheny County, Pennsylvania, T1D population, was first assessed for the EDC study between 1986
and 1988 (mean participant age and diabetes duration were 28 and 19 years, respectively) [9].
Subsequently, biennial examinations were conducted for 10 years, with a further detailed examination at
18 and 25 years from enrollment. All EDC study participants provided informed consent, and all study
procedures were approved by the University of Pittsburgh Institutional Review Board (IRB).
Demographic, health, self-care and medical history data were collected at each follow-up. Blood
pressure was measured with a random zero sphygmomanometer, after a five-minute rest  and
hypertension was defined as > 140/90 mmHg or use of antihypertensive medication. Automated high-
performance liquid chromatography (Diamat; Bio-Rad, Hercules, CA) was performed for Hemoglobin
A1c (HbA1c) [10]. Glomerular filtration rate was estimated by the CKD-EPI creatinine equation.
Retinopathy was classified according to the modified Airlie House classification; the methodology has
been described in detail elsewhere [11]. Proliferative retinopathy was defined as a grade of ≥60 in at
least one eye or a history of panretinal photocoagulation for proliferative diabetic retinopathy. To
achieve reasonable temporal comparability to the other cohorts, the current study used the years 1996-98
to define the baseline measure; 146 such participants (cases and controls) met the criteria and are
included in the present study. Annual rate of eGFR change was calculated using the difference between
the first (1996-98 exam) and last available eGFR (2001-03 or 2004-06 exam) and dividing by the
number of years between the two measures.
5
Coronary Artery Calcification in Type 1 Diabetes (CACTI) study cohort
The CACTI study enrolled 652 adults ranging in age from 19-56 years between 2000-2002 into a
prospective cohort study designed to examine cardiovascular and related complications of T1D [12]. All
participants were free of diagnosed cardiovascular disease, and did not have a cardiovascular event
(myocardial infarction, angioplasty or coronary artery bypass graft). Participants were either diagnosed
with T1D before the age of 30, or if diagnosed over age 30, they had positive autoantibodies or a clinical
course consistent with T1D. All were on insulin within a year of diagnosis and at the time of enrollment.
Participants have been followed longitudinally at three and six years for complications, including
diabetic nephropathy. All study participants provided informed consent, and the study was approved by
the Colorado Multiple IRB.
Demographic, health, self-care and medical history data were collected at baseline and at three
subsequent follow-up examinations. Blood pressure was measured three times via random zero
sphygmomanometer, after a five-minute rest, and the second and third measurements were averaged.
Hypertension was defined as >140/90 mmHg or use of antihypertensive medication. HbA1c was assayed
by high performance liquid chromatography (BioRad Variant). A participant was classified as having
retinopathy if he/she received laser treatment. Glomerular filtration rate was estimated by the CKD-EPI
creatinine equation. Average annual decline in eGFR was calculated as absolute change in eGFR from
the baseline exam to the last visit in the study divided by the number of years between these two visits.
The current analysis is based on 344 patients (with fast (cases) or slow (controls) kidney function
decline) from the CACT1 cohort.
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Intracellular adhesion molecule 1
Cathepsin D
Matrix metalloproteinase 7
Cytosolic non-specific dipeptidase 2
Insulin-like growth factor binding protein 2
Insulin-like growth factor binding protein 3
Insulin-like growth factor binding protein 7
Vascular cell adhesion protein 1





Endothelial cell-selective adhesion molecule
*326 lipid species measured across the listed lipid classes.
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Supplementary Table 2: Associations of clinical characteristics with rapid eGFR decline stratified
by baseline eGFR and UACR in the JDRF Biomarkers Consortium
Baseline eGFR Baseline UACR Combination of






60 < eGFR ≤90
ml/min/1.73m2
N (cases) = 511
(129)
90 < eGFR ≤ 120
ml/min/1.73m2
N (cases) = 638
(236)






































































































































Cell contents are odds ratios (95% CI) adjusted for age, sex, diabetes duration, and baseline HbA1c,
MAP, log2(UACR), and eGFR.
*Other combinations of UACR and eGFR strata had small cell-sizes, and hence were not evaluated.
The following interactions were significant at a p < 0.10:
- eGFR(90,120]*covariate interaction significant for log2(UACR) (p=0.002), baseline eGFR (P <
0.001); Reference category: eGFR[60,90]
- eGFR(120,150]*covariate interaction marginally significant for sex (p=0.09); significant for
log2(UACR) (p=0.04), baseline eGFR (P < 0.01); Reference category: eGFR(60,90
- Macroalbuminuria*covariate interaction significant for sex (p=0.02), HbA1c (p=0.01),
log2(UACR) (p=0.03), baseline eGFR (p < 0.001); Reference category: Normoalbuminuria group
- Microalbuminuria*covariate interaction significant for sex (p=0.01), HbA1c (p=0.047),
log2(UACR) (p = 0.048), baseline eGFR (p < 0.001)
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